The number of disease-modifying therapies (DMT) approved for the treatment of multiple sclerosis (MS) is expected to double to 2021, and this will intensify market fragmentation, according to new forecasts.
In this new era of enhanced therapeutic potential and complex treatment choices, fragmentation of the world's leading markets - France, Germany, Italy, Japan, Spain, the UK and the US - will intensify, as the MS field strives towards a more individualised approach to treatment, says the study, from Decision Resources.
Investigational MS therapies comprise a diverse mix of oral and parenteral agents, novel compounds, next-generation products and reformulations, the study points out. Among the new oral agents which are expected to launch during this time, Biogen Idec's oral immunomodulator BG-12 will have the greatest commercial success, with major-market sales of around $3 billion in 2017 as a result of clinical data that support a highly-favourable risk/benefit profile, Decision Resources forecasts.
Also in 2017, Novartis/Mitsubishi Tanabe Pharma's first-to-market oral agent Gilenya/Imusera (fingolimod) is expected to produce sales exceeding $2 billion in these major markets. However, other emerging oral competitors - including Sanofi/Genzyme's Aubagio (teriflunomide), which recently launched in the US - are not expecting to achieve blockbuster status, owning to more limited clinical advantages, it says.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/2479